Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986218 with or without nivolumab plus docetaxel in metastatic castration-resistant prostate cancer
2021-003990-74Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel + BMS-986218 with Docetaxel + BMS-986218 + nivolumab (2 arms). Primary endpoint: Incidence of adverse events and dose-limiting toxicities. Started Jul 2022; status: active.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2021-003990-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003990-74.